Sept 9 (Reuters) – Oxford Nanopore, a provider of rapid COVID-19 tests to Britain’s national health service, announced a London listing on Thursday as it aims to build on the 2.4 billion pound ($3.3 billion) valuation it achieved in its latest funding round.The life sciences company is planning a free float of at least 25% of its shares in the initial public offering (IPO) and said it was aiming to reduce its losses to breakeven in the next five years.A successful deal would be a major coup for the London Stock Exchange as most British pharma and life science companies tend to …
Related posts:
Esports Entertainment Group Reports Fourth Quarter and Fiscal Year 2021 Results
2021 is set to smash IPO records - Yahoo Finance
Philippine Tycoon Manuel Villar’s AllDay Marts Pegs IPO Price At Lower End Of Range; Still Plans REI...
Fertiglobe IPO price range implies equity value of up to $6 bln - Reuters
